| Original language | English (US) |
|---|---|
| Pages (from-to) | 1023-1026 |
| Number of pages | 4 |
| Journal | Journal of Cardiac Failure |
| Volume | 27 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2021 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Cardiac Failure, Vol. 27, No. 9, 09.2021, p. 1023-1026.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Changes in Stressed Blood Volume with Levosimendan in Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction
T2 - Insights Regarding Mechanism of Action From the HELP Trial
AU - Brener, Michael I.
AU - Hamid, Nadira B.
AU - Sunagawa, Kenji
AU - Borlaug, Barry A.
AU - Shah, Sanjiv J.
AU - Rich, Stuart
AU - Burkhoff, Daniel
N1 - Funding Information: Dr Borlaug has received research grants from the National Institutes of Health (R01 HL128526, U01 HL125205), AstraZeneca, Corvia, Medtronic, Mesoblast, GlaxoSmithKline, and TENAX Therapeutics; and advisory board/consulting for Aria, Actelion, Boehringer-Ingelheim, Imbria, Janssen, Merck, Novartis, Lilly, Novo Nordisk, Pfizer, and VADovations. Dr Shah has received research grants from the National Institutes of Health (R01 HL107577, R01 HL127028, R01 HL140731, and R01 HL149423), American Heart Association (16SFRN28780016), Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Axon Therapeutics, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Cardiora, CVRx, Cytokinetics, Eisai, GlaxoSmithKline, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi, Shifamed, TENAX, and United Therapeutics. Dr. Rich has consulted for Abbott, Medtronic, Boehringer-Ingelheim, and Novartis. Dr Burkhoff has received an institutional research grant from TENAX Therapeutics; and advisory board/consulting from Impulse Dynamics, Corvia Medical, and Axon Therapies. All other authors have no relevant disclosures.
PY - 2021/9
Y1 - 2021/9
UR - http://www.scopus.com/inward/record.url?scp=85110546843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110546843&partnerID=8YFLogxK
U2 - 10.1016/j.cardfail.2021.05.022
DO - 10.1016/j.cardfail.2021.05.022
M3 - Article
C2 - 34144177
AN - SCOPUS:85110546843
SN - 1071-9164
VL - 27
SP - 1023
EP - 1026
JO - Journal of Cardiac Failure
JF - Journal of Cardiac Failure
IS - 9
ER -